Print Clear

Prior Authorization Request Administrative Information

Member Information

Last name _____ First name _____ MI _____

Member ID _____ Date of birth _____

Sex assigned at birth ☐ Female ☐ Male ☐ "X" or Intersex

Current gender ☐ Female ☐ Male ☐ Transgender male ☐ Transgender female ☐ Other _____

Place of residence ☐ Home ☐ Nursing facility ☐ Other _____

Race/ethnicity _____ Preferred spoken language _____ Preferred written language _____

MassHealth does not exclude people or treat them differently because of race, color, national origin, age, disability, religion, creed, sexual orientation, or sex (including gender identity and gender stereotyping).

Plan Contact Information

Please indicate the member's MassHealth Plan and fax or submit this completed and signed form according to the Plan's contact information below.

MassHealth Fee-For-Service (FFS) Plan, Primary Care Clinician (PCC) Plan, Primary Care Accountable Care Organization (PCACO) Plan, Children's Medical Security Plan, and Health Safety Net Plan
☐ **MassHealth Drug Utilization Review Program** Pharmacy: Fax: (877) 208-7428 - Tel: (800) 745-7318
MassHealth Managed Care Organization (MCO) and Accountable Care Partnership Plans (ACPP)
☐ **Fallon Health** Online Prior Authorization: go.covermymeds.com/OptumRx Online Prior Authorization: providerportal.surescripts.net/ProviderPortal/optum Pharmacy: Fax: (844) 403-1029 - Tel: (844) 720-0033
☐ **Health New England** Online Prior Authorization: go.covermymeds.com/OptumRx Pharmacy: Fax: (800) 550-9246 - Tel: (800) 918-7545
☐ **Mass General Brigham Health Plan** Online Prior Authorization (Non-Specialty Drugs): go.covermymeds.com/OptumRx Online Prior Authorization (Specialty/Medical Drugs): provider.massgeneralbrighamhealthplan.org Pharmacy: Fax: (844) 403-1029 - Tel: (800) 711-4555
☐ **Tufts Health Plan** Online Prior Authorization: point32health.promptpa.com Pharmacy: Fax: (617) 673-0939 - Tel: (888) 257-1985
☐ **WellSense Health Plan** Online Prior Authorization: wellsense.org/providers/ma/pharmacy/prior-authorizations Pharmacy: Fax: (833) 951-1680 - Tel: (877) 417-1822

over

Topical Corticosteroids
Prior Authorization Request

MassHealth reviews requests for prior authorization (PA) on the basis of medical necessity only. If MassHealth approves the request, payment is still subject to all general conditions of MassHealth, including current member eligibility, other insurance, and program restrictions. MassHealth will notify the requesting provider and member of its decision. Keep a copy of this form for your records. If faxing this form, please use black ink.

Additional information about these agents, including PA requirements and preferred products, can be found within the MassHealth Drug List at **www.mass.gov/druglist.**

Medication information

Medication requested

Class I Superpotent products (See Sections I., II., and III.)

- ☐ clobetasol propionate (Impeklo, Olux-E): foam/emollient, lotion, shampoo-kit
- ☐ diflorasone: ointment
- ☐ halobetasol: foam
- ☐ halobetasol (Bryhali, Ultravate): lotion

Class II Potent products (See Sections I., II., and III.)

- ☐ betamethasone dipropionate (Sernivo): spray
- ☐ desoximetasone (Topicort): ointment, spray (0.25%), gel (0.05%)
- ☐ diflorasone (Apexicon-E): cream
- ☐ halcinonide (Halog): cream, solution

Class III Upper Mid-Strength Potent products (See Sections I., II., and III.)

- ☐ amcinonide: cream
- ☐ desoximetasone (Topicort): cream, ointment
- ☐ diflorasone: cream

Class IV Mid-Strength Potent products (See Sections I., II., and III.)

- ☐ clocortolone (Cloderm): cream
- ☐ fluocinolone (Synalar): ointment-kit
- ☐ flurandrenolide: ointment
- ☐ hydrocortisone valerate: ointment
- ☐ triamcinolone: ointment (0.05%), spray

Class V Lower Mid-Strength Potent products (See Sections I., II., and III.)

- ☐ desonide: lotion
- ☐ fluocinolone (Synalar): cream-kit
- ☐ flurandrenolide: cream, lotion
- ☐ fluticasone propionate: lotion
- ☐ hydrocortisone butyrate: lotion
- ☐ hydrocortisone butyrate/emollient: cream

Class VI Mild Potent products (See Sections I., II., and III.)

- ☐ fluocinolone (Synalar): solution-kit

Class VII Least Potent products (See Sections I., II., and III.)

- ☐ hydrocortisone: solution

Combination products

- ☐ betamethasone/calcipotriene (Taclonex): ointment, scalp suspension
- ☐ halobetasol/tazarotene (Duobrii): lotion
- ☐ neomycin/fluocinolone: cream, cream-kit

Strength and formulation requested

Frequency and duration of therapy **Drug NDC (if known)**

Indication(s) or ICD-10 code(s), if applicable

Section I. Please complete for all requests, excluding combination products.

Has the member had a trial with all topical corticosteroids of the same formulation and potency range that are available without prior authorization?

☐ Yes. Please list the specific drug name, dates/duration of use, and outcomes below*.

Drug name, strength, and formulation ______ Dates/duration of use ______
Did the member experience any of the following? ☐ Adverse reaction ☐ Inadequate response
Briefly describe details of adverse reaction or inadequate response.
______

Drug name, strength, and formulation ______ Dates/duration of use ______
Did the member experience any of the following? ☐ Adverse reaction ☐ Inadequate response
Briefly describe details of adverse reaction or inadequate response.
______

Drug name, strength, and formulation ______ Dates/duration of use ______
Did the member experience any of the following? ☐ Adverse reaction ☐ Inadequate response
Briefly describe details of adverse reaction or inadequate response.
______

Drug name, strength, and formulation ______ Dates/duration of use ______
Did the member experience any of the following? ☐ Adverse reaction ☐ Inadequate response
Briefly describe details of adverse reaction or inadequate response.
______

Drug name, strength, and formulation ______ Dates/duration of use ______
Did the member experience any of the following? ☐ Adverse reaction ☐ Inadequate response
Briefly describe details of adverse reaction or inadequate response.
______

☐ No. Please explain contraindication or clinical rationale for not using other topical corticosteroid(s) that are available without prior authorization in this member.
______

Section II. Please complete for foam and shampoo formulations in scalp-related conditions.

Has the member had a trial with one topical corticosteroid of a similar formulation and similar or greater potency range that is available without prior authorization?

☐ Yes. Please list the specific drug name, dates/duration of use, and outcomes below*.

Drug name, strength, and formulation ______ Dates/duration of use ______
Did the member experience any of the following? ☐ Adverse reaction ☐ Inadequate response
Briefly describe details of adverse reaction or inadequate response.
______

☐ No. Please explain contraindication or clinical rationale for not using other topical corticosteroid(s) that are available without prior authorization for this member.
______

over

Section III. Please complete for foam, gel, kit, shampoo, solution, and spray formulations.

Explain medical necessity for the requested formulation.

Section IV. Please complete for combination products.

1. Provide medical necessity for the combination product instead of the individual agents.
2. For Duobrii, has the member had a trial with one superpotent or potent topical corticosteroid?
   ☐ Yes. Please list the specific drug name, dates/duration of use, and outcomes below.*
   Drug name, strength, and formulation Dates/duration of use
   Did the member experience any of the following? ☐ Adverse reaction ☐ Inadequate response
   Briefly describe details of adverse reaction or inadequate response.
   ☐ No

Attach a letter with additional information regarding medication trials as applicable.

Section V. Please complete and provide documentation for exceptions to Step Therapy.

1. Is the alternative drug required under the step therapy protocol contraindicated, or will likely cause an adverse reaction in, or physical or mental harm to the member? ☐ Yes ☐ No
   If yes, briefly describe details of contraindication, adverse reaction, or harm.
2. Is the alternative drug required under the step therapy protocol expected to be ineffective based on the known clinical characteristics of the member and the known characteristics of the alternative drug regimen?
   ☐ Yes ☐ No
   If yes, briefly describe details of known clinical characteristics of member and alternative drug regimen.
3. Has the member previously tried the alternative drug required under the step therapy protocol, or another alternative drug in the same pharmacologic class or with the same mechanism of action, and such alternative drug was discontinued due to lack of efficacy or effectiveness, diminished effect, or an adverse event?
   ☐ Yes ☐ No
   If yes, please provide details for the previous trial.
   Drug name Dates/duration of use
   Did the member experience any of the following? ☐ Adverse reaction ☐ Inadequate response
   Briefly describe details of adverse reaction or inadequate response.
4. Is the member stable on the requested prescription drug prescribed by the health care provider, and switching drugs will likely cause an adverse reaction in or physical or mental harm to the member?
   ☐ Yes. Please provide details.
   ☐ No

over

Prior Authorization Request Prescriber and Provider Information

Prescriber Information

Last name* First name* MI

NPI* Individual MH Provider ID

DEA No. Office Contact Name

Address City State Zip

Email address

Telephone No.* Fax No.*

** Required*

Please also complete for professionally administered medications, if applicable.

Start date End date

Servicing prescriber/facility name ☐ Same as prescribing provider

Servicing provider/facility address

Servicing provider NPI/tax ID No.

Name of billing provider

Billing provider NPI No.

Is this a request for recertification? ☐ Yes ☐ No

CPT code No. of visits J code No. of units

Prescribing provider's attestation, signature, and date

I certify under the pains and penalties of perjury that I am the prescribing provider identified in the Prescriber information section of this form. Any attached statement on my letterhead has been reviewed and signed by me. I certify that the medical necessity information (per 130 CMR 450.204) on this form is true, accurate, and complete, to the best of my knowledge. I understand that I may be subject to civil penalties or criminal prosecution for any falsification, omission, or concealment of any material fact contained herein.

Prescribing provider's signature _____

Printed name of prescribing provider Date

(The form can either be signed by hand and then scanned, or it can be signed electronically using DocuSign or Adobe Sign. For electronic signatures, the signer can upload a picture of their wet signature. The typed text of a signature is not an acceptable form of an electronic signature.)